I-Corps: Rapid Ultrasensitive Biodetection Chip for Early Lung Cancer Diagnosis

这个I-Corps项目更广泛的影响/商业潜力是开发一种快速，超灵敏的生物标志物检测芯片，用于早期肺癌诊断。肺癌是癌症死亡的主要原因。2016年，这种癌症在美国夺去了大约15万人的生命，占所有癌症死亡人数的25%。由于其早期诊断困难和五年生存率低（18%），这种疾病是危险的。然而，如果早期发现，五年生存率可以大大提高到56%。事实上，迫切需要开发基于血液、唾液和尿液等简单体液的用户友好且低成本的早期肺癌诊断技术，以整合到定期健康检查中。为了满足这一需求，该项目旨在开发一个强大的便携式癌症生物标志物检测平台，用于从简单的体液中进行早期肺癌诊断。I-Corps项目是基于芯片上肺癌生物标志物检测平台的开发。目前，生物标志物感测的使用对于检测流体样品中的生物标志物的超灵敏度和高速而言本质上是困难的。 为了克服这一挑战，已经开发了一种光精确定位的生物分子浓缩技术，该技术允许同时聚焦和检测生物标志物。 所提出的技术可以在定期健康检查期间使用简单的体液（例如血液和唾液）在早期诊断肺癌时实现高保真度和准确度。 此外，这种诊断方法可能会加速纳米生物传感在实际应用中的应用，早期癌症diagnosis.This award reflects NSF's法定使命，并已被认为值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持.

The broader impact/commercial potential of this I-Corps project is the development of a rapid, ultrasensitive biomarker detection chip for applications in early lung cancer diagnosis. Lung cancer is the leading cause of cancerous deaths. This cancer claimed approximately 150,000 lives in the US in 2016, accounting for 25 percent of all cancer deaths. This disease is perilous due to the difficulties in its early-stage diagnosis and poor five-year survival rate (18%). Nevertheless, if detected early, the five-year survival rate can dramatically improve to 56%. Indeed, there is a dire need to develop user-friendly and low-cost, early-stage, lung-cancer diagnosis techniques based on simple body fluids, such as blood, saliva, and urine, for integration into regular wellness checks. In meeting this demand, this project seeks to develop a robust and portable cancer biomarker detection platform for early-stage lung cancer diagnosis from simple bodily fluids.This I-Corps project is based on the development of an on-chip lung-cancer biomarker detection platform. Currently, the use of biomarker sensing is intrinsically difficult for both ultra-sensitivity and high speed in detecting biomarkers in fluidic samples. To overcome this challenge, a light-pinpointed biomolecule concentrating technology that allows for simultaneous focusing and detection of biomarkers has been developed. The proposed technology may enable high fidelity and accuracy in diagnosing lung cancer at an early stage using simple bodily fluids, such as blood and saliva, during a regular wellness check. In addition, this diagnostic method may accelerate applications of nanobiosensing in practical, early-stage cancer diagnoses.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.